158 related articles for article (PubMed ID: 37816823)
1. Risk factor analysis for cisplatin-induced nephrotoxicity with the short hydration method in diabetic patients.
Saito Y; Kobayashi M; Tamaki S; Nakamura K; Hirate D; Takahashi K; Takekuma Y; Sakakibara-Konishi J; Shimizu Y; Kinoshita I; Sugawara M
Sci Rep; 2023 Oct; 13(1):17126. PubMed ID: 37816823
[TBL] [Abstract][Full Text] [Related]
2. Diabetes mellitus degenerates cisplatin-induced nephrotoxicity in short hydration method: a propensity score-matching analysis.
Saito Y; Sakamoto T; Takekuma Y; Kobayashi M; Okamoto K; Shinagawa N; Shimizu Y; Kinoshita I; Sugawara M
Sci Rep; 2022 Dec; 12(1):21819. PubMed ID: 36528725
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Prediabetes in Cisplatin-induced Nephrotoxicity in the Short Hydration Method: A Subgroup Analysis.
Saito Y; Sakamoto T; Kobayashi M; Takekuma Y; Higuchi I; Okamoto K; Sakakibara-Konishi J; Shimizu Y; Kinoshita I; Sugawara M
In Vivo; 2024; 38(2):800-806. PubMed ID: 38418143
[TBL] [Abstract][Full Text] [Related]
4. Administration of contrast media just before cisplatin-based chemotherapy increases cisplatin-induced nephrotoxicity.
Sendur MA; Aksoy S; Yaman S; Arik Z; Tugba Kos F; Akinci MB; Civelek B; Yildirim Ozdemir N; Uncu D; Zengin N
J BUON; 2013; 18(1):274-80. PubMed ID: 23613416
[TBL] [Abstract][Full Text] [Related]
5. Suitability of Oral Rehydration Solution (ORS) for Use in the Cisplatin Short Hydration Method.
Saito Y; Takekuma Y; Kobayashi M; Shinagawa N; Noguchi T; Takeuchi S; Shimizu Y; Kinoshita I; Dosaka-Akita H; Sugawara M
Anticancer Res; 2022 Jun; 42(6):3185-3193. PubMed ID: 35641251
[TBL] [Abstract][Full Text] [Related]
6. Impact of diabetic and pre-diabetic state on development of contrast-induced nephropathy in patients with chronic kidney disease.
Toprak O; Cirit M; Yesil M; Bayata S; Tanrisev M; Varol U; Ersoy R; Esi E
Nephrol Dial Transplant; 2007 Mar; 22(3):819-26. PubMed ID: 17090607
[TBL] [Abstract][Full Text] [Related]
7. Sodium bicarbonate versus isotonic saline for the prevention of contrast-induced nephropathy in patients with diabetes mellitus undergoing coronary angiography and/or intervention: a multicenter prospective randomized study.
Koc F; Ozdemir K; Altunkas F; Celik A; Dogdu O; Karayakali M; Gul EE; Erkorkmaz U; Kadi H; Akpek M; Kaya MG
J Investig Med; 2013 Jun; 61(5):872-7. PubMed ID: 23552179
[TBL] [Abstract][Full Text] [Related]
8. Risk stratification according to the type of impaired renal function in patients with acute myocardial infarction treated with percutaneous coronary intervention.
Kowalczyk J; Lenarczyk R; Kowalski O; Swiatkowski A; Stabryła-Deska J; Kurek T; Honisz G; Kukulski T; Gasior M; Kalarus Z
Kardiol Pol; 2007 Jun; 65(6):635-43; discussion 644. PubMed ID: 17629825
[TBL] [Abstract][Full Text] [Related]
9. A simple risk score model for predicting contrast-induced nephropathy after coronary angiography in patients with diabetes.
Zeng JF; Chen SQ; Ye JF; Chen Y; Lei L; Liu XQ; Liu Y; Wang Y; Lin JJ; Chen JY
Clin Exp Nephrol; 2019 Jul; 23(7):969-981. PubMed ID: 31049747
[TBL] [Abstract][Full Text] [Related]
10. N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial.
Amini M; Salarifar M; Amirbaigloo A; Masoudkabir F; Esfahani F
Trials; 2009 Jun; 10():45. PubMed ID: 19563648
[TBL] [Abstract][Full Text] [Related]
11. Prediction of contrast-induced nephropathy in diabetic patients undergoing elective cardiac catheterization or PCI: role of volume-to-creatinine clearance ratio and iodine dose-to-creatinine clearance ratio.
Worasuwannarak S; Pornratanarangsi S
J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S29-34. PubMed ID: 20364554
[TBL] [Abstract][Full Text] [Related]
12. Risk Factors Associated with Cisplatin-Induced Nephrotoxicity in Patients with Advanced Lung Cancer.
Miyoshi T; Misumi N; Hiraike M; Mihara Y; Nishino T; Tsuruta M; Kawamata Y; Hiraki Y; Kozono A; Ichiki M
Biol Pharm Bull; 2016; 39(12):2009-2014. PubMed ID: 27904042
[TBL] [Abstract][Full Text] [Related]
13. Association between contrast-induced nephrotoxicity and contrast enhanced computed tomography followed by endoscopic retrograde cholangiopancreatography.
Shinoura S; Tokushige A; Chinen K; Mori H; Kato S; Ueda S
Eur J Radiol; 2020 Aug; 129():109074. PubMed ID: 32473539
[TBL] [Abstract][Full Text] [Related]
14. Risk Factors for Cisplatin-Induced Nephrotoxicity: A Multicenter Retrospective Study.
Miyoshi T; Uoi M; Omura F; Tsumagari K; Maesaki S; Yokota C
Oncology; 2021; 99(2):105-113. PubMed ID: 32966986
[TBL] [Abstract][Full Text] [Related]
15. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods.
Stewart DJ; Dulberg CS; Mikhael NZ; Redmond MD; Montpetit VA; Goel R
Cancer Chemother Pharmacol; 1997; 40(4):293-308. PubMed ID: 9225947
[TBL] [Abstract][Full Text] [Related]
16. Risk factors and clinical outcomes for contrast-induced nephropathy after percutaneous coronary intervention in patients with normal serum creatinine.
Chong E; Poh KK; Liang S; Tan HC
Ann Acad Med Singap; 2010 May; 39(5):374-80. PubMed ID: 20535427
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: a prospective, multicenter, randomized study to analyze the effect of hydration and acetylcysteine.
Chen SL; Zhang J; Yei F; Zhu Z; Liu Z; Lin S; Chu J; Yan J; Zhang R; Kwan TW
Int J Cardiol; 2008 Jun; 126(3):407-13. PubMed ID: 17651830
[TBL] [Abstract][Full Text] [Related]
18. The lack of benefit of a combination of an angiotensin receptor blocker and calcium channel blocker on contrast-induced nephropathy in patients with chronic kidney disease.
Oguzhan N; Cilan H; Sipahioglu M; Unal A; Kocyigit I; Kavuncuoglu F; Arikan T; Akpek M; Elcik D; Sahin O; Gulme E; Pala C; Tokgoz B; Utas C; Oguzhan A; Oymak O
Ren Fail; 2013; 35(4):434-9. PubMed ID: 23413781
[TBL] [Abstract][Full Text] [Related]
19. Multivariate analysis of risk factors for cisplatin-induced nephrotoxicity in gynecological cancer.
Yamamoto Y; Watanabe K; Matsushita H; Tsukiyama I; Matsuura K; Wakatsuki A
J Obstet Gynaecol Res; 2017 Dec; 43(12):1880-1886. PubMed ID: 28984058
[TBL] [Abstract][Full Text] [Related]
20. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media.
McCullough PA; Bertrand ME; Brinker JA; Stacul F
J Am Coll Cardiol; 2006 Aug; 48(4):692-9. PubMed ID: 16904536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
